Literature DB >> 18548110

Functional polymorphisms of the FAS gene associated with risk of vitiligo in Chinese populations: a case-control analysis.

Miao Li1, Dongjie Sun, Chunying Li, Zhengdong Zhang, Lin Gao, Kai Li, Hong Li, Tianwen Gao.   

Abstract

The FAS/FASLG system plays a key role in regulating apoptosis. Previous findings have shown that CD4-dependent destruction of melanocytes is partially inhibited by blocking FAS-FASLG interactions in autoimmune vitiligo. Functional polymorphisms of the FAS and FASLG genes can alter their transcriptional activities. In a hospital-based case-control study of 750 vitiligo patients and 756 controls, we genotyped the FAS-1377 G>A, FAS-670 A>G, and FASLG-844 T>C polymorphisms and assessed their association with the risk of vitiligo. We found that a significantly increased risk of vitiligo was associated with the FAS-1377 AA genotype (adjusted odds ratio (OR), 1.49; 95% confidence interval (CI), 1.07-2.08) and the FAS-1377 AG genotype (adjusted OR, 1.31; 95% CI, 1.05-1.63) when compared with the FAS-1377 GG genotype. However, no evident risk was associated with FAS-670 G>A genotypes. In the combined analysis of the two variant alleles of FAS, genotypes with 3 to 4 risk alleles were associated with an increased risk of vitiligo compared with those having 0-2 variants (adjusted OR, 2.87; 95% CI, 1.90-4.32). In conclusion, genetic variants in the FAS gene may affect the risk of vitiligo in Chinese populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18548110     DOI: 10.1038/jid.2008.161

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

2.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

3.  Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.

Authors:  Stanca A Birlea; Ying Jin; Dorothy C Bennett; Deborah M Herbstman; Margaret R Wallace; Wayne T McCormack; E Helen Kemp; David J Gawkrodger; Anthony P Weetman; Mauro Picardo; Giovanni Leone; Alain Taïeb; Thomas Jouary; Khaled Ezzedine; Nanja van Geel; Jo Lambert; Andreas Overbeck; Pamela R Fain; Richard A Spritz
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

4.  Association analysis of FAS-670A/G and FASL-844C/T polymorphisms with risk of generalized aggressive periodontitis disease.

Authors:  Rezvan Asgari; Kheirollah Yari; Kamran Mansouri; Mitra Bakhtiari
Journal:  Biomed Rep       Date:  2018-02-08

5.  Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets.

Authors:  Rama Dey-Rao; Animesh A Sinha
Journal:  BMC Genomics       Date:  2017-01-28       Impact factor: 3.969

6.  Association between FAS gene -670 A/G and -1377 G/A polymorphisms and the risk of autoimmune diseases: a meta-analysis.

Authors:  Hongwei Yan; Yuxiao Hong; Yunfei Cai
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

7.  Three new single nucleotide polymorphisms identified by a genome-wide association study in Korean patients with vitiligo.

Authors:  Kyung Ah Cheong; Nan-Hyung Kim; Minsoo Noh; Ai-Young Lee
Journal:  J Korean Med Sci       Date:  2013-05-02       Impact factor: 2.153

8.  Evaluation of skin expression profiles of patients with vitiligo treated with narrow-band UVB therapy by targeted RNA-seq.

Authors:  Jorge Ocampo-Candiani; Mauricio Salinas-Santander; Victor Trevino; Rocio Ortiz-López; Jorge Ocampo-Garza; Celia Nohemi Sanchez-Dominguez
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

Review 9.  Mechanisms of melanocyte death in vitiligo.

Authors:  Jianru Chen; Shuli Li; Chunying Li
Journal:  Med Res Rev       Date:  2020-11-17       Impact factor: 12.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.